Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients

Brain Tumor Pathology

Volumn 27, Issue 1, 2010, Pages 29-34

  Chiba, Yasuyoshi ^a   Hashimoto, Naoya ^a   Tsuboi, Akihiro ^a   Rabo, Carter ^a   Oka, Yoshihiro ^a   Kinoshita, Manabu ^a   Kagawa, Naoki ^a   Oji, Yusuke ^a   Sugiyama, Haruo ^a   Yoshimine, Toshiki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glioblastoma; Immunotherapy; MIB 1 staining index; Prognostic value; Wilms' tumor 1

Indexed keywords

CANCER VACCINE; KI 67 ANTIGEN; UNCLASSIFIED DRUG; WT1 PEPTIDE VACCINE; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR LOCALIZATION;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROGNOSIS; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; YOUNG ADULT;

EID: 77951788033     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-010-0265-9     Document Type: Article

References (19)

1. A.J. Clark W.G. Dos Santos J. Mccready, et al. 2007 Wilms tumor 1 expression in malignant gliomas and correlation of 1KTS isoforms with p53 status J Neurosurg 107 586 592 10.3171/JNS-07/09/0586 1:CAS:528:DC%2BD2sXhtVequrvP 17886559 (Pubitemid 47451043)
2. H.D. Menssen E. Bertelmann S. Bartelt, et al. 2000 Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens J Cancer Res Clin Oncol 126 226 232 10.1007/s004320050037 1:CAS:528:DC%2BD3cXjtl2lurc%3D 10782896
3. S. Izumoto A. Tsuboi Y. Oka, et al. 2008 Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme J Neurosurg 108 963 971 10.3171/JNS/2008/108/5/0963 1:CAS:528: DC%2BD1cXmtFSrsrw%3D 18447714 (Pubitemid 351656845)
4. P. Therasse S.G. Arbuck E.A. Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Institute 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D (Pubitemid 30099779)
5. M.J. Coppes C.E. Campbell B.R.G. Williams 1993 The role of WT1 in Wilms tumorigenesis FASEB J 7 886 895 1:CAS:528:DyaK3sXmsVKrtr4%3D 8393819
6. Y. Oka K. Udaka A. Tsuboi, et al. 2000 Cancer immunotherapy targeting Wilms' tumor gene WT1 product J Immunol 164 1873 1880 1:CAS:528: DC%2BD3cXhtlymtLw%3D 10657636
7. H. Sugiyama 2002 Cancer immunotherapy targeting WT1 protein Int J Hematol 76 127 132 10.1007/BF02982574 1:CAS:528:DC%2BD38XntlWjsb4%3D 12215010
8. K. Inoue H. Ogawa Y. Sonoda, et al. 1997 Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia Blood 89 1405 1412 1:CAS:528: DyaK2sXhtFantLs%3D 9028964
9. D.M. Loeb E. Evron C.B. Patel, et al. 2001 Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumorspecific promoter methylation Cancer Res 61 921 925 1:CAS:528:DC%2BD3MXhsFSrurw%3D 11221883
10. Y. Oji S. Miyoshi H. Maeda, et al. 2002 Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers Int J Cancer 100 297 303 10.1002/ijc.10476 1:CAS:528:DC%2BD38Xlt1Shsbg%3D 12115544 (Pubitemid 34728987)
11. C.E. Campbell N.P. Kuriyan R.R. Rackley, et al. 1998 Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma Int J Cancer 78 182 188 10.1002/(SICI)1097-0215(19981005)78:2<182::AID- IJC11>3.0.CO;2-D 1:CAS:528:DyaK1cXmsVals70%3D 9754650 (Pubitemid 28443175)
12. T. Ueda Y. Oji N. Naka, et al. 2003 Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas Cancer Sci 94 271 276 10.1111/j.1349-7006.2003.tb01432.x 1:CAS:528:DC%2BD3sXktVCqsLw%3D 12824921 (Pubitemid 36575894)
13. Y. Oka A. Tsuboi Y. Oji, et al. 2008 WT1 peptide vaccine for the treatment of cancer Curr Opin Immunol 20 211 220 10.1016/j.coi.2008.04.009 1:CAS:528:DC%2BD1cXntlSktro%3D 18502632
14. M.A. Cheever J.P. Allison A.S. Ferris, et al. 2009 The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research Clin Cancer Res 15 5323 5337 10.1158/1078-0432.CCR-09- 0737 19723653
15. T. Hashiba S. Izumoto N. Hashimoto, et al. 2007 Expression of WT1 protein and correlation with cellular proliferation in glial tumors Neurol Med Chir (Tokyo) 47 165 170 10.2176/nmc.47.165
16. R. Stupp W.P. Mason M.J. van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D 15758009 (Pubitemid 40349501)
17. A. Tsuboi Y. Oka H. Ogawa, et al. 2000 Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination J Clin Immunol 20 195 202 10.1023/A:1006637529995 1:CAS:528:DC%2BD3cXlvVSis7Y%3D 10941827 (Pubitemid 30485880)
18. S. Moskowitz T. Jin R. Prayson 2006 Role of MIB1 in predicting survival in patients with glioblastomas J Neuro-Oncol 76 193 200 10.1007/s11060-005-5262- 1 (Pubitemid 43125748)
19. J. Vaquero M. Zurita C. Morales, et al. 2000 Prognostic significance of endothelial surface score and MIB-1 labeling index in glioblastoma J Neuro-Oncol 46 11 16 10.1023/A:1006347919565 1:STN:280:DC%2BD3M%2Fhtlalsg%3D%3D (Pubitemid 30352608)